The guidance was formed after PIPA found that information provided in response to patient enquiries varied significantly between companies. More: PIPA releases patient enquiries guidance Source: News
read moreABPI Brexit preparations include ensuring continued UK participation in EU regulatory and medicines safety processes. More: ABPI details Brexit plans at PIPA conference Source: News
read morePlans will support existing efforts to reduce medicine shortages to protect NHS patients. More: Gov't moves to curb HRT shortages Source: News
read moreThe committee felt that comparison to existing treatments for the condition was “unreliable and lacked validity”. More: NICE draft 'no' for Roche's Tecentriq Source: News
read moreThe FDA has changed its tune about the levels of a suspected carcinogen in Zantac and generic ranitidine drugs. Instead of just a little NDMA with a very low risk, the agency says its new “early, limited testing” has found
read moreEli Lilly and Bayer are in the clear. A set of whistleblower lawsuits alleging drugmakers ran “white-coat marketing” schemes—by offering nursing and reimbursement services as kickbacks—generated buzz in the industry, but government prosecutors looked into the claims and opted not to move forward. More: Lilly,
read more© 1994 - 2026 B.M. Pharmaceuticals